25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ROVI (Rovi) Stock Analysis
Buy, Hold or Sell?

Let's analyze Rovi together

I guess you are interested in Laboratorios Farmaceuticos ROVI. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Rovi’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Rovi’s Price Targets

I'm going to help you getting a better view of Laboratorios Farmaceuticos ROVI. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Laboratorios Farmaceuticos ROVI

I send you an email if I find something interesting about Laboratorios Farmaceuticos ROVI.

1. Quick Overview

1.1. Quick analysis of Rovi (30 sec.)










1.2. What can you expect buying and holding a share of Rovi? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
77.5%

What is your share worth?

Current worth
€11.72
Expected worth in 1 year
€13.23
How sure are you?
87.5%

+ What do you gain per year?

Total Gains per Share
€1.51
Return On Investment
2.7%

For what price can you sell your share?

Current Price per Share
€56.20
Expected price per share
€50.05 - €66.55
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Rovi (5 min.)




Live pricePrice per Share (EOD)
€56.20
Intrinsic Value Per Share
€-72.62 - €15.67
Total Value Per Share
€-60.90 - €27.39

2.2. Growth of Rovi (5 min.)




Is Rovi growing?

Current yearPrevious yearGrowGrow %
How rich?$706.1m$630.6m$23.6m3.6%

How much money is Rovi making?

Current yearPrevious yearGrowGrow %
Making money$61.5m$40.5m$21m34.1%
Net Profit Margin19.7%16.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Rovi (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Rovi?

Welcome investor! Rovi's management wants to use your money to grow the business. In return you get a share of Rovi.

First you should know what it really means to hold a share of Rovi. And how you can make/lose money.

Speculation

The Price per Share of Rovi is €56.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rovi.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rovi, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €11.72. Based on the TTM, the Book Value Change Per Share is €0.38 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rovi.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.420.7%1.182.1%1.031.8%1.172.1%0.971.7%0.561.0%
Usd Book Value Change Per Share0.410.7%0.450.8%-0.13-0.2%0.380.7%0.330.6%0.250.4%
Usd Dividend Per Share0.000.0%0.000.0%0.380.7%0.530.9%0.480.8%0.290.5%
Usd Total Gains Per Share0.410.7%0.450.8%0.250.4%0.911.6%0.811.4%0.541.0%
Usd Price Per Share60.66-80.57-69.14-67.29-63.73-41.67-
Price to Earnings Ratio36.38-24.66-26.53-21.90-22.73-61.50-
Price-to-Total Gains Ratio146.92-47.81-79.34-57.39-95.69-100.78-
Price to Book Ratio4.39-6.61-5.74-5.83-6.12-5.09-
Price-to-Total Gains Ratio146.92-47.81-79.34-57.39-95.69-100.78-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share66.19798
Number of shares15
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.48
Usd Book Value Change Per Share0.450.33
Usd Total Gains Per Share0.450.81
Gains per Quarter (15 shares)6.6912.13
Gains per Year (15 shares)26.7548.52
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102717292039
205344574088
3080718660137
401079811480186
50134125143100235
60160152171120284
70187179200140333
80214206228160382
90241233257180431
100267260286200480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%69.01.01.097.2%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%15.05.00.075.0%33.07.00.082.5%56.08.07.078.9%
Dividend per Share0.00.04.00.0%7.00.05.058.3%15.00.05.075.0%31.00.09.077.5%47.00.024.066.2%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%17.03.00.085.0%35.05.00.087.5%61.06.04.085.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Laboratorios Farmaceuticos ROVI compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3510.378-7%-0.113+132%0.319+10%0.282+24%0.212+65%
Book Value Per Share--11.72110.648+10%10.207+15%9.958+18%8.937+31%6.539+79%
Current Ratio--3.7052.832+31%2.410+54%2.453+51%2.623+41%2.607+42%
Debt To Asset Ratio--0.2640.341-23%0.351-25%0.371-29%0.366-28%0.360-27%
Debt To Equity Ratio--0.3640.543-33%0.551-34%0.612-41%0.592-39%0.571-36%
Dividend Per Share----0%0.324-100%0.453-100%0.404-100%0.249-100%
Enterprise Value--2419498250.0003319942412.125-27%2838498279.778-15%2772664508.769-13%2688712202.342-10%1750156274.791+38%
Eps--0.3541.002-65%0.878-60%0.993-64%0.827-57%0.474-25%
Ev To Sales Ratio--3.9053.866+1%3.832+2%3.483+12%3.802+3%3.237+21%
Free Cash Flow Per Share--0.2070.386-47%0.217-5%0.362-43%0.420-51%0.195+6%
Free Cash Flow To Equity Per Share--0.2070.211-2%-0.622+401%-0.066+132%0.002+10797%0.012+1570%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--15.673----------
Intrinsic Value_10Y_min---72.621----------
Intrinsic Value_1Y_max--1.469----------
Intrinsic Value_1Y_min---0.592----------
Intrinsic Value_3Y_max--4.491----------
Intrinsic Value_3Y_min---7.580----------
Intrinsic Value_5Y_max--7.606----------
Intrinsic Value_5Y_min---20.871----------
Market Cap2874377100.000+8%2633993250.0003587221162.125-27%3067799029.778-14%3010792842.103-13%2889785702.342-9%1887300424.791+40%
Net Profit Margin--0.1170.197-41%0.167-30%0.199-41%0.201-42%0.142-18%
Operating Margin---0.224-100%0.218-100%0.247-100%0.247-100%0.170-100%
Operating Ratio--1.2670.848+49%0.783+62%0.778+63%0.766+65%0.838+51%
Pb Ratio4.795+8%4.3946.614-34%5.739-23%5.829-25%6.116-28%5.092-14%
Pe Ratio39.699+8%36.37924.664+47%26.530+37%21.896+66%22.733+60%61.502-41%
Price Per Share56.200+8%51.50068.400-25%58.698-12%57.128-10%54.102-5%35.376+46%
Price To Free Cash Flow Ratio67.991+8%62.30596.419-35%35.967+73%42.376+47%49.710+25%27.545+126%
Price To Total Gains Ratio160.329+8%146.92147.812+207%79.343+85%57.395+156%95.686+54%100.777+46%
Quick Ratio--0.9210.863+7%0.841+10%0.911+1%1.050-12%1.205-24%
Return On Assets--0.0220.062-64%0.042-47%0.054-59%0.051-57%0.035-36%
Return On Equity--0.0310.095-68%0.064-52%0.086-64%0.082-62%0.055-44%
Total Gains Per Share--0.3510.378-7%0.212+66%0.772-55%0.687-49%0.461-24%
Usd Book Value--706113357.200654311082.050+8%630676813.025+12%618148766.783+14%562080864.205+26%410845718.843+72%
Usd Book Value Change Per Share--0.4130.446-7%-0.133+132%0.375+10%0.333+24%0.250+65%
Usd Book Value Per Share--13.80612.542+10%12.023+15%11.729+18%10.527+31%7.703+79%
Usd Dividend Per Share----0%0.382-100%0.534-100%0.476-100%0.293-100%
Usd Enterprise Value--2849926988.6753910560167.242-27%3343467123.750-15%3265921524.879-13%3167034103.138-10%2061509076.076+38%
Usd Eps--0.4171.181-65%1.034-60%1.169-64%0.975-57%0.558-25%
Usd Free Cash Flow--12449225.10023580085.625-47%13256381.075-6%22468835.133-45%26487201.720-53%12167559.763+2%
Usd Free Cash Flow Per Share--0.2430.455-47%0.255-5%0.427-43%0.495-51%0.230+6%
Usd Free Cash Flow To Equity Per Share--0.2430.249-2%-0.733+401%-0.078+132%0.002+10797%0.015+1570%
Usd Market Cap3385728786.090+8%3102580649.1754225387806.867-27%3613560477.175-14%3546412888.713-13%3403878578.788-9%2223051170.361+40%
Usd Price Per Share66.198+8%60.66280.568-25%69.140-12%67.290-10%63.726-5%41.669+46%
Usd Profit--21321167.90061594746.800-65%40589550.575-47%53112001.792-60%46783125.460-54%27154217.043-21%
Usd Revenue--182447286.800295282450.450-38%229411926.650-20%254774273.133-28%221963358.210-18%155492694.360+17%
Usd Total Gains Per Share--0.4130.446-7%0.249+66%0.909-55%0.809-49%0.543-24%
 EOD+4 -4MRQTTM+12 -24YOY+17 -213Y+15 -235Y+14 -2410Y+23 -15

3.3 Fundamental Score

Let's check the fundamental score of Laboratorios Farmaceuticos ROVI based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1539.699
Price to Book Ratio (EOD)Between0-14.795
Net Profit Margin (MRQ)Greater than00.117
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.921
Current Ratio (MRQ)Greater than13.705
Debt to Asset Ratio (MRQ)Less than10.264
Debt to Equity Ratio (MRQ)Less than10.364
Return on Equity (MRQ)Greater than0.150.031
Return on Assets (MRQ)Greater than0.050.022
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Laboratorios Farmaceuticos ROVI based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.141
Ma 20Greater thanMa 5055.328
Ma 50Greater thanMa 10053.792
Ma 100Greater thanMa 20052.956
OpenGreater thanClose55.750
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios FarmaceΓΊticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Fundamental data was last updated by Penke on 2025-07-02 11:52:07.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is overpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Rovi earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Rovi to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 11.7%Β means thatΒ €0.12 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 11.7%. The company is making a huge profit. +2
  • The TTM is 19.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ11.7%TTM19.7%-8.0%
TTM19.7%YOY16.7%+3.0%
TTM19.7%5Y20.1%-0.3%
5Y20.1%10Y14.2%+5.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Rovi is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Rovi to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 2.2% Return on Assets means thatΒ Rovi generatedΒ €0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 2.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 6.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ2.2%TTM6.2%-3.9%
TTM6.2%YOY4.2%+2.0%
TTM6.2%5Y5.1%+1.0%
5Y5.1%10Y3.5%+1.6%
4.3.1.3. Return on Equity

Shows how efficient Rovi is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Rovi to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 3.1% Return on Equity means Rovi generated €0.03Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 3.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 9.5%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.1%TTM9.5%-6.4%
TTM9.5%YOY6.4%+3.1%
TTM9.5%5Y8.2%+1.3%
5Y8.2%10Y5.5%+2.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Laboratorios Farmaceuticos ROVI.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Rovi is operatingΒ .

  • Measures how much profit Rovi makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Rovi to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM22.4%-22.4%
TTM22.4%YOY21.8%+0.6%
TTM22.4%5Y24.7%-2.4%
5Y24.7%10Y17.0%+7.7%
4.3.2.2. Operating Ratio

Measures how efficient Rovi is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.27 means that the operating costs are €1.27 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 1.267. The company is inefficient in keeping operating costs low. -1
  • The TTM is 0.848. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ1.267TTM0.848+0.419
TTM0.848YOY0.783+0.065
TTM0.8485Y0.766+0.082
5Y0.76610Y0.838-0.072
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Laboratorios Farmaceuticos ROVI.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Rovi is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.70Β means the company has €3.70 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 3.705. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.832. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.705TTM2.832+0.873
TTM2.832YOY2.410+0.422
TTM2.8325Y2.623+0.209
5Y2.62310Y2.607+0.017
4.4.3.2. Quick Ratio

Measures if Rovi is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Rovi to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.92Β means the company can pay off €0.92 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.921. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.863. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.921TTM0.863+0.058
TTM0.863YOY0.841+0.022
TTM0.8635Y1.050-0.188
5Y1.05010Y1.205-0.154
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Laboratorios Farmaceuticos ROVI.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of RoviΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Rovi to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.26Β means that Rovi assets areΒ financed with 26.4% credit (debt) and the remaining percentage (100% - 26.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.264. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.341. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.264TTM0.341-0.078
TTM0.341YOY0.351-0.009
TTM0.3415Y0.366-0.025
5Y0.36610Y0.360+0.006
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Rovi is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Rovi to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 36.4% means that company has €0.36 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.364. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.543. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.364TTM0.543-0.179
TTM0.543YOY0.551-0.008
TTM0.5435Y0.592-0.050
5Y0.59210Y0.571+0.021
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Rovi generates.

  • Above 15 is considered overpriced butΒ always compareΒ Rovi to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 36.38 means the investor is paying €36.38Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The EOD is 39.699. Based on the earnings, the company is overpriced. -1
  • The MRQ is 36.379. Based on the earnings, the company is overpriced. -1
  • The TTM is 24.664. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD39.699MRQ36.379+3.320
MRQ36.379TTM24.664+11.715
TTM24.664YOY26.530-1.865
TTM24.6645Y22.733+1.931
5Y22.73310Y61.502-38.770
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The EOD is 67.991. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 62.305. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 96.419. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD67.991MRQ62.305+5.686
MRQ62.305TTM96.419-34.115
TTM96.419YOY35.967+60.452
TTM96.4195Y49.710+46.709
5Y49.71010Y27.545+22.165
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Rovi is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 4.39 means the investor is paying €4.39Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The EOD is 4.795. Based on the equity, the company is fair priced.
  • The MRQ is 4.394. Based on the equity, the company is fair priced.
  • The TTM is 6.614. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.795MRQ4.394+0.401
MRQ4.394TTM6.614-2.221
TTM6.614YOY5.739+0.876
TTM6.6145Y6.116+0.498
5Y6.11610Y5.092+1.024
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets813,963
Total Liabilities214,495
Total Stockholder Equity589,873
 As reported
Total Liabilities 214,495
Total Stockholder Equity+ 589,873
Total Assets = 813,963

Assets

Total Assets813,963
Total Current Assets467,855
Long-term Assets346,108
Total Current Assets
Cash And Cash Equivalents 29,306
Net Receivables 116,244
Inventory 319,412
Total Current Assets  (as reported)467,855
Total Current Assets  (calculated)464,962
+/- 2,893
Long-term Assets
Property Plant Equipment 288,189
Long-term Assets  (as reported)346,108
Long-term Assets  (calculated)288,189
+/- 57,919

Liabilities & Shareholders' Equity

Total Current Liabilities126,277
Long-term Liabilities88,218
Total Stockholder Equity589,873
Total Current Liabilities
Accounts payable 90,839
Total Current Liabilities  (as reported)126,277
Total Current Liabilities  (calculated)90,839
+/- 35,438
Long-term Liabilities
Long-term Liabilities  (as reported)88,218
Long-term Liabilities  (calculated)0
+/- 88,218
Total Stockholder Equity
Retained Earnings 503,426
Total Stockholder Equity (as reported)589,873
Total Stockholder Equity (calculated)503,426
+/- 86,447
Other
Capital Stock3,074
Common Stock Shares Outstanding 51,145
Net Invested Capital 589,873
Net Working Capital 341,578



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-03-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
48,602
80,977
89,606
103,480
0
115,736
112,159
115,884
115,884
135,905
135,905
145,403
145,403
164,787
164,787
0
208,259
0
212,887
216,512
217,912
218,307
228,068
219,266
219,267
216,920
222,363
224,992
229,376
236,089
235,923
236,591
247,640
245,329
261,320
261,880
264,596
262,089
263,847
265,401
278,595
271,324
287,848
301,942
303,004
289,626
298,382
307,319
312,247
316,158
402,700
427,665
449,121
452,174
511,211
526,660
543,830
561,714
574,439
591,382
644,245
685,066
732,676
744,859
791,565
772,466
878,703
885,195
899,832
830,725
799,884
778,663
857,325
877,848
832,022
813,963
813,963832,022877,848857,325778,663799,884830,725899,832885,195878,703772,466791,565744,859732,676685,066644,245591,382574,439561,714543,830526,660511,211452,174449,121427,665402,700316,158312,247307,319298,382289,626303,004301,942287,848271,324278,595265,401263,847262,089264,596261,880261,320245,329247,640236,591235,923236,089229,376224,992222,363216,920219,267219,266228,068218,307217,912216,512212,8870208,2590164,787164,787145,403145,403135,905135,905115,884115,884112,159115,7360103,48089,60680,97748,602
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
161,931
165,517
164,937
164,723
169,177
160,986
145,350
132,111
131,042
134,195
142,570
144,450
137,483
138,296
155,846
149,623
162,033
163,444
160,748
157,348
154,083
153,884
166,861
158,888
167,072
181,116
182,894
168,446
168,167
177,017
181,573
183,881
254,004
245,528
266,864
269,537
317,885
334,895
351,465
366,856
364,578
386,142
439,297
476,502
506,362
521,958
566,934
543,620
623,073
631,586
637,965
567,063
509,331
485,415
540,781
553,829
491,575
467,855
467,855491,575553,829540,781485,415509,331567,063637,965631,586623,073543,620566,934521,958506,362476,502439,297386,142364,578366,856351,465334,895317,885269,537266,864245,528254,004183,881181,573177,017168,167168,446182,894181,116167,072158,888166,861153,884154,083157,348160,748163,444162,033149,623155,846138,296137,483144,450142,570134,195131,042132,111145,350160,986169,177164,723164,937165,517161,931000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
58,635
38,673
52,593
58,934
49,491
37,519
36,489
21,623
16,585
22,193
22,361
17,065
19,401
12,866
25,219
28,241
26,671
27,855
25,673
25,576
29,251
39,930
44,612
40,721
41,378
47,662
54,122
44,171
40,700
38,965
29,966
17,474
95,511
71,308
66,680
42,525
67,426
55,938
35,428
35,283
53,162
72,617
126,746
143,961
99,035
101,736
157,627
97,639
124,945
141,462
153,812
56,377
25,322
13,085
44,578
17,554
27,186
29,306
29,30627,18617,55444,57813,08525,32256,377153,812141,462124,94597,639157,627101,73699,035143,961126,74672,61753,16235,28335,42855,93867,42642,52566,68071,30895,51117,47429,96638,96540,70044,17154,12247,66241,37840,72144,61239,93029,25125,57625,67327,85526,67128,24125,21912,86619,40117,06522,36122,19316,58521,62336,48937,51949,49158,93452,59338,67358,635000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,000
6,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32
0
32
0
47
0
59
0
67
0
69
0
80
0
0
0
0
-65
-65
-65
-65
-65
1,225
-65
-65
-65
1,606
-65
-65
0
540
0
227
0
022705400-65-651,606-65-65-651,225-65-65-65-65-650000800690670590470320320000000000000000006,0006,0000000000000000000000000
       Net Receivables 
20,736
27,976
28,478
27,414
0
40,531
39,398
44,742
44,742
46,506
46,506
42,537
42,537
58,919
58,919
0
56,079
0
60,317
60,113
63,443
65,573
71,203
72,912
58,017
58,633
57,037
60,518
62,400
66,443
43,846
62,884
49,681
56,988
52,372
64,888
51,033
56,837
46,150
51,301
60,403
51,825
45,327
59,488
48,464
48,123
41,117
54,985
60,185
60,393
62,200
62,456
70,218
72,738
89,895
84,309
79,795
91,989
82,046
92,479
112,023
109,596
150,172
169,159
140,269
150,182
180,011
160,398
126,379
138,267
143,314
131,488
120,834
185,509
129,502
116,244
116,244129,502185,509120,834131,488143,314138,267126,379160,398180,011150,182140,269169,159150,172109,596112,02392,47982,04691,98979,79584,30989,89572,73870,21862,45662,20060,39360,18554,98541,11748,12348,46459,48845,32751,82560,40351,30146,15056,83751,03364,88852,37256,98849,68162,88443,84666,44362,40060,51857,03758,63358,01772,91271,20365,57363,44360,11360,317056,079058,91958,91942,53742,53746,50646,50644,74244,74239,39840,531027,41428,47827,97620,736
       Other Current Assets 
194
60
888
2,230
0
308
0
0
0
0
0
0
0
0
0
0
0
0
61,472
25,000
11,000
65,573
72,380
72,912
59,662
58,633
58,232
60,518
63,622
556
15,426
1,140
14,816
917
15,360
1,473
14,049
1,856
14,762
935
60,403
732
12,949
1,934
6,899
2,330
10,811
1,283
60,185
3,459
63,632
3,455
78,601
6,924
91,648
3,299
408
1,939
84,217
2,552
2,265
813
161,854
173,068
2,669
3,867
186,184
2,668
4,768
6,740
146,041
2,871
19,343
4,104
4,656
0
04,6564,10419,3432,871146,0416,7404,7682,668186,1843,8672,669173,068161,8548132,2652,55284,2171,9394083,29991,6486,92478,6013,45563,6323,45960,1851,28310,8112,3306,8991,93412,94973260,40393514,7621,85614,0491,47315,36091714,8161,14015,42655663,62260,51858,23258,63359,66272,91272,38065,57311,00025,00061,47200000000000030802,23088860194
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,956
50,995
52,975
53,584
58,891
58,280
73,917
84,809
91,321
90,797
86,806
91,639
98,440
98,295
91,794
95,706
99,287
98,436
103,848
104,741
109,764
111,517
111,734
112,436
120,776
120,826
120,110
121,180
130,215
130,302
130,674
132,277
148,696
182,137
182,257
182,637
193,326
191,765
192,365
194,858
209,861
205,240
204,948
208,564
226,314
222,901
224,631
228,846
255,630
253,609
261,867
263,662
290,553
293,248
316,544
324,019
342,416
346,108
346,108342,416324,019316,544293,248290,553263,662261,867253,609255,630228,846224,631222,901226,314208,564204,948205,240209,861194,858192,365191,765193,326182,637182,257182,137148,696132,277130,674130,302130,215121,180120,110120,826120,776112,436111,734111,517109,764104,741103,84898,43699,28795,70691,79498,29598,44091,63986,80690,79791,32184,80973,91758,28058,89153,58452,97550,99550,956000000000000000000
       Property Plant Equipment 
3,208
5,549
11,332
14,034
0
17,863
21,577
26,401
26,401
29,817
29,817
31,290
31,290
32,539
32,539
0
40,975
0
42,659
42,644
42,842
43,077
45,857
46,580
47,411
49,394
53,791
53,724
54,725
56,098
60,199
59,840
62,235
65,138
73,593
72,496
77,227
77,864
81,803
80,725
80,400
80,813
82,822
81,370
81,089
81,724
89,056
89,129
89,095
90,592
95,837
117,283
121,064
122,988
131,608
130,755
131,293
136,862
155,395
154,962
159,426
165,191
181,775
179,126
182,648
187,474
215,541
215,463
223,785
226,655
253,652
256,616
261,214
269,597
286,622
288,189
288,189286,622269,597261,214256,616253,652226,655223,785215,463215,541187,474182,648179,126181,775165,191159,426154,962155,395136,862131,293130,755131,608122,988121,064117,28395,83790,59289,09589,12989,05681,72481,08981,37082,82280,81380,40080,72581,80377,86477,22772,49673,59365,13862,23559,84060,19956,09854,72553,72453,79149,39447,41146,58045,85743,07742,84242,64442,659040,975032,53932,53931,29031,29029,81729,81726,40126,40121,57717,863014,03411,3325,5493,208
       Goodwill 
0
1,441
1,441
1,441
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5,940
0
0
0
000-5,940000000000000000000000000000000000000000000000000000000000000000000001,4411,4411,4410
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,641
2,544
2,351
2,348
2,123
2,108
2,098
2,080
2,108
2,147
2,098
1,972
1,914
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001,9141,9722,0982,1472,1082,0802,0982,1082,1232,3482,3512,5442,641000000000000000000000000000000000000000000
       Intangible Assets 
1,191
1,449
1,460
1,469
0
731
749
762
762
745
745
743
743
974
974
0
1,275
0
2,290
2,320
2,686
2,668
2,736
2,754
2,892
2,937
3,176
3,155
5,779
8,702
14,468
14,393
14,742
15,239
17,206
17,287
17,567
17,812
18,881
18,551
18,665
18,603
24,872
26,459
25,829
25,212
27,078
26,589
26,233
25,993
34,650
47,395
47,012
46,130
45,079
0
43,151
0
41,413
40,522
39,690
38,887
38,558
0
36,901
0
35,744
0
34,249
0
33,902
0
27,092
32,663
33,950
0
033,95032,66327,092033,902034,249035,744036,901038,55838,88739,69040,52241,413043,151045,07946,13047,01247,39534,65025,99326,23326,58927,07825,21225,82926,45924,87218,60318,66518,55118,88117,81217,56717,28717,20615,23914,74214,39314,4688,7025,7793,1553,1762,9372,8922,7542,7362,6682,6862,3202,29001,275097497474374374574576276274973101,4691,4601,4491,191
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,086
2,100
322
324
6,325
6,132
132
26,531
28,281
27,374
134
19,287
16,256
16,256
6,683
6,811
208
208
209
209
209
2,759
2,860
2,917
2,830
2,659
2,466
2,463
2,188
2,173
2,163
2,145
2,173
2,212
2,163
2,037
1,979
2,011
1,956
1,945
1,948
1,996
2,079
2,143
2,131
2,211
1,290
2,184
2,267
2,278
1,671
2,781
656
901
8,602
2,180
292
0
02922,1808,6029016562,7811,6712,2782,2672,1841,2902,2112,1312,1432,0791,9961,9481,9451,9562,0111,9792,0372,1632,2122,1732,1452,1632,1732,1882,4632,4662,6592,8302,9172,8602,7592092092092082086,8116,68316,25616,25619,28713427,37428,28126,5311326,1326,3253243222,1002,086000000000000000000
> Total Liabilities 
30,797
40,038
44,308
62,126
0
65,360
60,235
52,722
52,722
67,190
67,190
75,156
75,156
77,582
77,582
0
109,681
0
108,753
107,569
109,640
106,855
114,087
100,158
99,021
93,346
95,916
92,513
95,983
95,867
91,459
86,623
96,483
90,837
102,850
96,742
105,326
99,864
99,062
91,419
103,095
92,311
104,442
111,921
112,882
98,190
106,695
108,694
119,133
115,057
115,228
133,213
149,814
138,367
188,825
190,347
191,587
192,257
200,739
194,038
240,383
232,034
261,700
319,160
391,215
329,182
357,324
316,399
380,047
276,087
256,390
254,881
374,563
319,660
250,482
214,495
214,495250,482319,660374,563254,881256,390276,087380,047316,399357,324329,182391,215319,160261,700232,034240,383194,038200,739192,257191,587190,347188,825138,367149,814133,213115,228115,057119,133108,694106,69598,190112,882111,921104,44292,311103,09591,41999,06299,864105,32696,742102,85090,83796,48386,62391,45995,86795,98392,51395,91693,34699,021100,158114,087106,855109,640107,569108,7530109,681077,58277,58275,15675,15667,19067,19052,72252,72260,23565,360062,12644,30840,03830,797
   > Total Current Liabilities 
24,127
26,068
31,904
40,249
0
40,123
34,520
27,221
27,221
35,413
35,413
41,755
41,755
38,719
38,719
0
55,035
0
51,627
48,303
51,956
49,246
56,756
52,281
56,862
52,144
55,132
52,507
61,467
62,215
58,340
54,082
63,821
46,822
62,117
57,164
68,146
56,092
59,226
53,856
68,526
60,447
76,442
66,686
69,857
58,717
73,223
80,186
91,191
85,839
87,512
89,398
104,913
95,036
106,709
108,534
111,556
111,815
122,889
118,342
167,373
159,434
190,388
248,705
320,569
258,337
293,887
255,405
321,594
220,774
199,843
191,246
272,455
221,489
156,651
126,277
126,277156,651221,489272,455191,246199,843220,774321,594255,405293,887258,337320,569248,705190,388159,434167,373118,342122,889111,815111,556108,534106,70995,036104,91389,39887,51285,83991,19180,18673,22358,71769,85766,68676,44260,44768,52653,85659,22656,09268,14657,16462,11746,82263,82154,08258,34062,21561,46752,50755,13252,14456,86252,28156,75649,24651,95648,30351,627055,035038,71938,71941,75541,75535,41335,41327,22127,22134,52040,123040,24931,90426,06824,127
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,545
9,434
8,120
1,983
8,780
9,255
9,339
8,406
8,625
8,400
8,718
4,286
4,409
4,274
4,949
5,843
8,241
10,147
11,479
12,671
13,353
12,966
13,001
13,024
14,303
16,208
18,135
19,069
18,878
17,635
17,453
14,614
14,483
12,701
5,441
5,768
6,003
6,022
5,335
-31,032
5,214
6,400
6,225
-124,550
6,814
12,697
12,427
11,960
11,580
13,185
22,146
23,015
33,997
23,691
0
023,69133,99723,01522,14613,18511,58011,96012,42712,6976,814-124,5506,2256,4005,214-31,0325,3356,0226,0035,7685,44112,70114,48314,61417,45317,63518,87819,06918,13516,20814,30313,02413,00112,96613,35312,67111,47910,1478,2415,8434,9494,2744,4094,2868,7188,4008,6258,4069,3399,2558,7801,9838,1209,4348,545000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,794
51,300
49,135
14,303
16,208
18,135
19,069
18,878
17,635
17,453
14,614
7,283
9,112
0
0
0
2,028
0
0
0
2,959
0
2,788
0
8,238
0
0
0
8,060
0
0
0
17,842
0
017,8420008,0600008,23802,78802,9590002,0280009,1127,28314,61417,45317,63518,87819,06918,13516,20814,30349,13551,30033,794000000000000000000000000000000000000000000
       Accounts payable 
16,730
12,136
18,119
22,469
0
24,246
23,042
18,598
18,598
23,643
23,643
32,399
32,399
24,877
24,877
0
23,329
0
46,053
42,204
8,578
34,589
33,507
38,313
27,235
37,352
32,005
37,141
46,691
46,887
34,421
39,250
34,714
39,665
46,601
49,275
35,113
44,640
36,982
39,080
37,057
44,011
50,221
49,926
35,698
40,017
42,129
57,881
50,970
63,413
47,875
70,125
68,501
80,166
68,770
100,487
73,168
86,544
63,452
81,178
71,516
101,430
97,407
133,376
97,564
126,237
123,901
135,331
107,934
113,637
107,593
106,639
80,876
124,270
86,851
90,839
90,83986,851124,27080,876106,639107,593113,637107,934135,331123,901126,23797,564133,37697,407101,43071,51681,17863,45286,54473,168100,48768,77080,16668,50170,12547,87563,41350,97057,88142,12940,01735,69849,92650,22144,01137,05739,08036,98244,64035,11349,27546,60139,66534,71439,25034,42146,88746,69137,14132,00537,35227,23538,31333,50734,5898,57842,20446,053023,329024,87724,87732,39932,39923,64323,64318,59818,59823,04224,246022,46918,11912,13616,730
       Other Current Liabilities 
6,626
11,523
11,607
11,055
0
12,811
8,681
4,606
4,606
6,250
6,250
2,546
2,546
8,033
8,033
0
21,091
0
5,574
6,099
43,207
5,917
13,815
5,605
27,644
43,364
13,872
6,027
4,338
6,703
15,519
6,114
24,821
2,748
11,242
2,940
27,190
3,211
12,097
3,297
18,798
3,083
13,255
3,759
21,135
4,397
14,886
4,170
21,152
3,548
22,002
1,820
21,798
387
25,238
2,606
32,620
19,265
53,415
30,247
52,743
52,790
85,900
102,247
83,659
113,098
157,248
98,626
198,789
76,294
73,810
52,739
156,195
63,222
43,725
0
043,72563,222156,19552,73973,81076,294198,78998,626157,248113,09883,659102,24785,90052,79052,74330,24753,41519,26532,6202,60625,23838721,7981,82022,0023,54821,1524,17014,8864,39721,1353,75913,2553,08318,7983,29712,0973,21127,1902,94011,2422,74824,8216,11415,5196,7034,3386,02713,87243,36427,6445,60513,8155,91743,2076,0995,574021,09108,0338,0332,5462,5466,2506,2504,6064,6068,68112,811011,05511,60711,5236,626
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
57,126
59,266
57,684
57,609
57,331
47,877
42,159
41,202
40,784
40,006
34,516
33,652
33,119
32,541
32,662
44,015
40,733
39,578
37,180
43,772
39,836
37,563
34,569
31,864
28,000
45,235
43,025
39,473
33,472
28,508
27,942
29,218
27,716
43,815
44,901
43,331
82,116
81,813
80,031
80,442
77,850
75,696
73,010
72,600
71,312
70,455
70,646
70,845
63,437
60,994
58,453
55,313
56,547
63,635
102,108
98,171
93,831
88,218
88,21893,83198,171102,10863,63556,54755,31358,45360,99463,43770,84570,64670,45571,31272,60073,01075,69677,85080,44280,03181,81382,11643,33144,90143,81527,71629,21827,94228,50833,47239,47343,02545,23528,00031,86434,56937,56339,83643,77237,18039,57840,73344,01532,66232,54133,11933,65234,51640,00640,78441,20242,15947,87757,33157,60957,68459,26657,126000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,378
0
59,441
0
54,540
0
0
0
0
0
0
0
000000054,540059,441066,3780000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-8,545
-9,434
-8,120
-1,983
-8,780
-9,255
-9,339
-8,406
-8,625
-8,400
-8,718
-4,286
-4,409
-4,274
-4,949
-5,843
-8,241
-10,147
-11,479
-12,671
-13,353
-12,966
-13,001
-13,024
-14,303
-16,208
-18,135
-19,069
-18,878
-17,635
-17,453
4,495
-14,483
8,170
-5,441
-5,768
-6,003
11,524
-5,335
31,032
-5,214
11,263
-6,225
142,118
-6,814
5,159
-12,427
-11,960
-11,580
5,607
-22,146
-23,015
-33,997
-7,626
0
0-7,626-33,997-23,015-22,1465,607-11,580-11,960-12,4275,159-6,814142,118-6,22511,263-5,21431,032-5,33511,524-6,003-5,768-5,4418,170-14,4834,495-17,453-17,635-18,878-19,069-18,135-16,208-14,303-13,024-13,001-12,966-13,353-12,671-11,479-10,147-8,241-5,843-4,949-4,274-4,409-4,286-8,718-8,400-8,625-8,406-9,339-9,255-8,780-1,983-8,120-9,434-8,545000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,746
0
02,74600000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,240
0
6,113
0
8,429
0
8,386
0
8,371
0
8,150
0
7,929
0
7,708
0
7,487
0
7,266
0
7,045
0
6,824
0
6,603
0
0
0
0
0
0
0
0
0
0000000006,60306,82407,04507,26607,48707,70807,92908,15008,37108,38608,42906,11304,240000000000000000000000000000000000000000000
> Total Stockholder Equity
17,805
40,914
45,283
41,351
25,810
50,375
51,924
63,162
63,162
68,715
68,715
70,247
70,247
87,205
87,205
87,205
98,578
0
104,134
108,943
108,272
111,452
113,981
119,108
120,246
123,574
126,447
132,479
133,393
140,222
144,464
149,968
151,157
154,492
158,470
165,138
159,270
162,225
164,785
173,982
175,500
179,013
183,406
190,021
190,122
191,436
191,687
198,625
193,114
201,101
287,472
294,452
299,307
313,807
322,386
336,313
352,243
369,457
373,700
397,344
403,862
453,032
470,976
425,553
399,022
441,921
520,012
567,259
516,643
551,501
539,387
519,677
476,092
548,680
572,028
589,873
589,873572,028548,680476,092519,677539,387551,501516,643567,259520,012441,921399,022425,553470,976453,032403,862397,344373,700369,457352,243336,313322,386313,807299,307294,452287,472201,101193,114198,625191,687191,436190,122190,021183,406179,013175,500173,982164,785162,225159,270165,138158,470154,492151,157149,968144,464140,222133,393132,479126,447123,574120,246119,108113,981111,452108,272108,943104,134098,57887,20587,20587,20570,24770,24768,71568,71563,16263,16251,92450,37525,81041,35145,28340,91417,805
   Common Stock
214
10,674
9,936
3,454
0
147
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
0
3,000
0
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,241
3,241
3,241
3,241
3,241
3,241
3,241
3,241
3,074
3,074
0
03,0743,0743,2413,2413,2413,2413,2413,2413,2413,2413,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,00003,00003,0003,0003,0003,0003,0003,0003,0003,0003,00014703,4549,93610,674214
   Retained Earnings 
2,035
30,233
34,351
37,704
0
50,174
48,861
60,048
60,048
68,478
68,478
71,045
71,045
85,482
85,482
0
97,405
0
102,496
107,348
12,874
109,674
112,047
5,257
12,959
16,632
125,206
130,664
132,325
137,506
141,965
147,895
148,923
153,846
157,685
164,211
162,893
165,982
169,299
178,721
180,389
184,005
188,510
194,934
194,845
196,243
196,496
203,411
198,117
206,202
204,687
211,823
216,820
231,742
241,057
256,392
273,448
293,516
302,215
329,550
338,711
390,754
445,426
498,453
472,475
384,351
456,031
502,010
451,719
504,667
555,534
570,492
542,996
464,472
486,213
503,426
503,426486,213464,472542,996570,492555,534504,667451,719502,010456,031384,351472,475498,453445,426390,754338,711329,550302,215293,516273,448256,392241,057231,742216,820211,823204,687206,202198,117203,411196,496196,243194,845194,934188,510184,005180,389178,721169,299165,982162,893164,211157,685153,846148,923147,895141,965137,506132,325130,664125,20616,63212,9595,257112,047109,67412,874107,348102,496097,405085,48285,48271,04571,04568,47868,47860,04860,04848,86150,174037,70434,35130,2332,035
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87,636
0
87,636
0
0
87,636
0
87,636
0
87,636
0
0
0
0
0
0
0
000000087,636087,636087,6360087,636087,63600000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000-28,7200-23,876000000000-8,698-8,600-8,383-8,407-8,405-8,321-8,511-8,701-8,589-8,486-8,336-8,112-7,355-7,221-2,672-2,813-2,739-1,061-1,208-782-585-2,267-1,540-2,060-2,148-2,077-1,880-1,922-1,938-2,064-2,003-1,9600-1,8250-1,198-1,198-4,087-4,087-2,602-2,602000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,362
-1,405
92,398
-1,222
-1,066
110,851
104,287
103,942
-1,759
-1,185
-1,932
-585
-782
-1,208
-1,061
-2,739
-2,813
-2,672
-7,221
-7,355
-8,112
-8,336
-8,486
-8,589
-8,701
-8,511
-7,721
-8,405
-8,407
-8,383
-8,600
-8,698
78,824
78,668
78,453
78,031
77,295
75,888
74,762
71,908
67,451
63,760
61,116
-2
21,515
-76,932
-77,484
53,662
60,075
61,346
61,034
42,924
-20,040
-54,695
-70,116
81,159
82,741
0
082,74181,159-70,116-54,695-20,04042,92461,03461,34660,07553,662-77,484-76,93221,515-261,11663,76067,45171,90874,76275,88877,29578,03178,45378,66878,824-8,698-8,600-8,383-8,407-8,405-7,721-8,511-8,701-8,589-8,486-8,336-8,112-7,355-7,221-2,672-2,813-2,739-1,061-1,208-782-585-1,932-1,185-1,759103,942104,287110,851-1,066-1,22292,398-1,405-1,362000000000000000000



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.




6.4. Cash Flows

Currency in EUR. All numbers in thousands.




6.5. Income Statements

Currency in EUR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue763,749
Cost of Revenue-285,403
Gross Profit478,346478,346
 
Operating Income (+$)
Gross Profit478,346
Operating Expense-298,801
Operating Income179,545179,545
 
Operating Expense (+$)
Research Development0
Selling General Administrative17,688
Selling And Marketing Expenses21,737
Operating Expense298,80139,425
 
Net Interest Income (+$)
Interest Income26
Interest Expense-1,988
Other Finance Cost-129
Net Interest Income-2,091
 
Pretax Income (+$)
Operating Income179,545
Net Interest Income-2,091
Other Non-Operating Income Expenses0
Income Before Tax (EBT)177,690181,400
EBIT - interestExpense = 177,690
177,695
138,869
Interest Expense1,988
Earnings Before Interest and Taxes (EBIT)179,678179,678
Earnings Before Interest and Taxes (EBITDA)207,693
 
After tax Income (+$)
Income Before Tax177,690
Tax Provision-40,814
Net Income From Continuing Ops136,876136,876
Net Income136,881
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses584,204
Total Other Income/Expenses Net-1,8552,091
 

Technical Analysis of Rovi
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rovi. The general trend of Rovi is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rovi's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Rovi Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Laboratorios Farmaceuticos ROVI.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 56.95 < 57.20 < 66.55.

The bearish price targets are: 53.25 > 50.90 > 50.05.

Know someone who trades $ROVI? Share this with them.πŸ‘‡

Laboratorios Farmaceuticos ROVI Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Laboratorios Farmaceuticos ROVI. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Laboratorios Farmaceuticos ROVI Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Laboratorios Farmaceuticos ROVI. The current macd is 0.44639589.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Rovi price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Rovi. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Rovi price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Laboratorios Farmaceuticos ROVI Daily Moving Average Convergence/Divergence (MACD) ChartLaboratorios Farmaceuticos ROVI Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Laboratorios Farmaceuticos ROVI. The current adx is 15.25.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Rovi shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Laboratorios Farmaceuticos ROVI Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Laboratorios Farmaceuticos ROVI. The current sar is 53.42.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Laboratorios Farmaceuticos ROVI Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Laboratorios Farmaceuticos ROVI. The current rsi is 62.14. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Laboratorios Farmaceuticos ROVI Daily Relative Strength Index (RSI) ChartLaboratorios Farmaceuticos ROVI Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Laboratorios Farmaceuticos ROVI. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Rovi price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Laboratorios Farmaceuticos ROVI Daily Stochastic Oscillator ChartLaboratorios Farmaceuticos ROVI Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Laboratorios Farmaceuticos ROVI. The current cci is 65.71.

Laboratorios Farmaceuticos ROVI Daily Commodity Channel Index (CCI) ChartLaboratorios Farmaceuticos ROVI Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Laboratorios Farmaceuticos ROVI. The current cmo is 32.11.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Laboratorios Farmaceuticos ROVI Daily Chande Momentum Oscillator (CMO) ChartLaboratorios Farmaceuticos ROVI Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Laboratorios Farmaceuticos ROVI. The current willr is -4.83870968.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Laboratorios Farmaceuticos ROVI Daily Williams %R ChartLaboratorios Farmaceuticos ROVI Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Laboratorios Farmaceuticos ROVI.

Laboratorios Farmaceuticos ROVI Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Laboratorios Farmaceuticos ROVI. The current atr is 0.98270246.

Laboratorios Farmaceuticos ROVI Daily Average True Range (ATR) ChartLaboratorios Farmaceuticos ROVI Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Laboratorios Farmaceuticos ROVI. The current obv is 1,787,294.

Laboratorios Farmaceuticos ROVI Daily On-Balance Volume (OBV) ChartLaboratorios Farmaceuticos ROVI Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Laboratorios Farmaceuticos ROVI. The current mfi is 66.52.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Laboratorios Farmaceuticos ROVI Daily Money Flow Index (MFI) ChartLaboratorios Farmaceuticos ROVI Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Laboratorios Farmaceuticos ROVI.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-07-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Laboratorios Farmaceuticos ROVI Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Laboratorios Farmaceuticos ROVI based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.141
Ma 20Greater thanMa 5055.328
Ma 50Greater thanMa 10053.792
Ma 100Greater thanMa 20052.956
OpenGreater thanClose55.750
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Rovi with someone you think should read this too:
  • Are you bullish or bearish on Rovi? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rovi? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Laboratorios Farmaceuticos ROVI

I send you an email if I find something interesting about Laboratorios Farmaceuticos ROVI.


Comments

How you think about this?

Leave a comment

Stay informed about Laboratorios Farmaceuticos ROVI.

Receive notifications about Laboratorios Farmaceuticos ROVI in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.